The estimated Net Worth of Biosciences Inc Neurocrine is at least $53.9 Million dollars as of 23 February 2023. Biosciences Neurocrine owns over 4,395,588 units of Voyager Therapeutics Inc stock worth over $53,852,984 and over the last 6 years Biosciences sold VYGR stock worth over $0.
Biosciences has made over 2 trades of the Voyager Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Biosciences bought 4,395,588 units of VYGR stock worth $39,032,821 on 23 February 2023.
The largest trade Biosciences's ever made was buying 4,395,588 units of Voyager Therapeutics Inc stock on 23 February 2023 worth over $39,032,821. On average, Biosciences trades about 4,287,658 units every 722 days since 2019. As of 23 February 2023 Biosciences still owns at least 8,575,316 units of Voyager Therapeutics Inc stock.
You can see the complete history of Biosciences Neurocrine stock trades at the bottom of the page.
Biosciences's mailing address filed with the SEC is 12780, El Camino Real, San Diego, San Diego County, California, 92014, United States.
Over the last 9 years, insiders at Voyager Therapeutics Inc have traded over $22,599,571 worth of Voyager Therapeutics Inc stock and bought 9,198,716 units worth $93,782,260 . The most active insiders traders include Sanofi, Capital, Llc Eco R1 und Biosciences Inc Neurocrine. On average, Voyager Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $966,976. The most recent stock trade was executed by Robin Swartz on 2 April 2024, trading 1,357 units of VYGR stock currently worth $13,407.
voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.
Voyager Therapeutics Inc executives and other stock owners filed with the SEC include: